Key facts
- It has raised $220K; the latest was Seed Round ($220K) in Aug 2025.
- Notable investors include Kingsley Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for GensimBio
- ·The full record, as it builds
Funding rounds
No funding rounds for GensimBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GensimBio
Developer of protein-based biomaterials designed for use in cosmetic, medical, and pharmaceutical applications. The company's platform incorporates proprietary protein engineering techniques to produce high-functionality materials that are vegan-compatible and aligned with environmental and social standards, enabling the global skincare and biomedical markets to access scalable, sustainable, and application-specific solutions for dermacosmetics, hydrogels, and drug delivery systems.
- Sector
- Healthcare
- HQ
- Daegu, South Korea
- Founded
- 2021
- Employees
- 4
- Website
- genismbio.com/
- Ownership
- Privately Held (backing)
GensimBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GensimBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GensimBio in its N-PORT filings yet. We sweep new filings monthly.